베르베린 (대사)
Berberine (Metabolism)
📚 관련 논문 (21편)
1. Clin Mol Hepatol. 2026 Jan;32(1):221-238. doi: 10.3350/cmh.2025.0577. Epub 2025 Oct 14. Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production. Tu D(1), Lu C(1), Guo J(1), Chen Q(1), Li X(1), Wang Y(1), Cheng L(1), Jian
2. Biomed Chromatogr. 2019 Jul;33(7):e4514. doi: 10.1002/bmc.4514. Epub 2019 Mar 19. Metabolism-based herb-drug interaction of Corydalis Bungeanae Herba with berberine in vitro and in vivo in rats. Mao X(1), Zhao H(1), Wang Q(1), Li H(1), Yang L(1), Hu Z(1), Zhang F(1), Guo X(1), Peng Y(1), Zhe
3. Molecules. 2016 Apr 8;21(4):464. doi: 10.3390/molecules21040464. In Vivo and in Vitro Study on Drug-Drug Interaction of Lovastatin and Berberine from Pharmacokinetic and HepG2 Cell Metabolism Studies. Cui H(1), Wang J(2), Zhang Q(3), Dang M(4), Liu H(5), Dong Y(6), Zhang L(7), Yang F(8), Wu J
4. PLoS One. 2011 Apr 4;6(4):e18127. doi: 10.1371/journal.pone.0018127. Antimicrobial and efflux pump inhibitory activity of caffeoylquinic acids from Artemisia absinthium against gram-positive pathogenic bacteria. Fiamegos YC(1), Kastritis PL, Exarchou V, Han H, Bonvin AM, Vervoort J, Lewis K,
5. J Agric Food Chem. 2003 Sep 10;51(19):5677-9. doi: 10.1021/jf0302714. Isoflavones as potentiators of antibacterial activity. Morel C(1), Stermitz FR, Tegos G, Lewis K. Author information: (1)Department of Chemistry, Colorado State University, Fort Collins, CO 80523-1872, USA. Isoflavones iso
6. Pharmacol Toxicol. 2001 May;88(5):232-7. doi: 10.1034/j.1600-0773.2001.d01-109.x. Protective effect of berberine on cyclophosphamide-induced haemorrhagic cystitis in rats. Xu X(1), Malavé A. Author information: (1)Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern
1. Eur J Nutr. 2025 Feb 25;64(2):102. doi: 10.1007/s00394-025-03618-9. The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial. Mansour A(#)(1), Sajjadi-Jazi SM(#)(1), Gerami H(1)(2), Khorasanian AS(1)(3), Moalemzadeh B(4), Karimi S(5), Afrakoti NM(6), Mofid V(7), Mohajeri-Tehrani MR(1), Hekmatdoost A(8). Author information: (1)Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. (2)Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. (3)Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. (4)Department of Internal Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. (5)Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, 46, West Arghavan St., Farahzadi Blvd., Shahrak Gharb, Tehran, Iran. (6)Anesthesiology and Critical Care Department, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. (7)Department of Food Science and Technology, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran. (8)Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, 46, West Arghavan St., Farahzadi Blvd., Shahrak Gharb, Tehran, Iran. a_hekmat2000@yahoo.com. (#)Contributed equally BACKGROUND: Diabetes is a serious global health issue and increases the risk of several chronic diseases. However, if hyperglycemia and other metabolic abnormalities related to diabetes are controlled, fewer micro- and macrovascular complications may occur. OBJECTIVE: To investigate whether daily supplementation with berberine in combination with cinnamon could have effect on cardiometabolic risk factors, such as impaired glucose regulation, dyslipidemia, and hypertension in patients with diabetes. METHODS: Patients with type 2 diabetes were recruited to participate in a parallel, double-blind, placebo-controlled, randomized study. Participants were randomized into berberine in combination with cinnamon supplementation or placebo group. Participants were then asked to take a divided daily dose of 1200 mg berberine and 600 mg cinnamon or placebo for 12 weeks. ANCOVA was then performed to evaluate the differences between the two groups, controlling for the respective baseline values. RESULTS: At the end of study, fasting blood sugar (FBS) (P = 0.031) and hemoglobin A1C (HbA1c) (P = 0.013) were significantly lower in participants taking berberine plus cinnamon than those taking the placebo capsules. The results of the serum lipid profile also indicated a significant difference in the level of low density lipoprotein cholesterol (LDL-C) (P = 0.039), while no difference was observed in the levels of total cholesterol, high density lipoprotein cholesterol (HDL-C), and triglycerides between the study groups. In addition, there was no difference in other measured metabolic and anthropometric parameters between the two groups. CONCLUSION: Twelve weeks of berberine plus cinnamon consumption reduced blood FBS, HbA1c and LDL-C concentration in patients with diabetes. © 2025. Springer-Verlag GmbH Germany, part of Springer Nature. DOI: 10.1007/s00394-025-03618-9 PMID: 39998703 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Consent for publication: Not applicable. Competing interests: It should be emphasized that Dr. Vahid Mofid is an employee of Pajoohesh Gostran Taghzie asan® Company. Other authors have not conflicts of interest or financial ties to disclose.
2. Clin Transl Sci. 2025 Feb;18(2):e70120. doi: 10.1111/cts.70120. The Pharmacokinetic Interaction Between Metformin and the Natural Product Goldenseal Is Metformin Dose-Dependent: A Three-Arm Crossover Study in Adults With Type 2 Diabetes. Nguyen JT(1), Arian CM(2), Tanna RS(1), Cherel MG(1), Layton ME(3), White JR(4), Thummel KE(2)(5), Paine MF(1)(5). Author information: (1)Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA. (2)Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, USA. (3)Elson S. Floyd College of Medicine, Washington State University, Spokane, Washington, USA. (4)Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA. (5)Center of Excellence for Natural Product Drug Interaction Research, Spokane, Washington, USA. Pharmacokinetic drug interactions can lead to unexpected changes in plasma concentrations of the object drug, potentially increasing the risk for adverse effects and/or decreasing therapeutic efficacy. The botanical product goldenseal was previously shown to decrease metformin systemic exposure in healthy adults. This three-arm, open-label, crossover clinical study assessed the pharmacokinetic goldenseal-metformin interaction in adults with type 2 diabetes stabilized on therapeutic doses of metformin (500-2550 mg daily). The aggregate pharmacokinetic data indicated no clinically meaningful interaction as determined by the metformin area under the plasma concentration-time curve (AUC) geometric mean ratio [90% confidence interval] of 0.93 [0.86-1.01] laying within the predefined no-effect range (0.80-1.25). However, metformin AUC decreased by ~20%, 14%, and 0% after goldenseal coadministration at low (500-750 mg), moderate (1000-1500 mg), and high (2000-2550 mg) metformin doses, respectively; renal clearance and half-life remained unchanged throughout. The exploratory pharmacodynamic endpoint, HbA1c, decreased on average from 6.8% to 6.5%, regardless of the effects of goldenseal on metformin pharmacokinetics. The decreasing effect of goldenseal on metformin systemic exposure with increasing metformin dose, coupled with no changes in renal excretion and elimination half-life, indicated that both the pharmacokinetic goldenseal-metformin interaction and the nonlinear absorption of metformin are governed by saturable, intestinal transport mechanism(s). The disconnect between changes in metformin systemic exposure and therapeutic effects emphasizes the need to evaluate clinical biomarkers to comprehensively assess drug interaction risks, particularly those involving natural products. Healthcare providers may consider cautioning patients about supplementing metformin pharmacotherapy with goldenseal to avoid risks for undesired changes in glycemic control. Trial Registration: ClinicalTrials.gov identifier: NCT05081583. © 2025 The Author(s). Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. DOI: 10.1111/cts.70120 PMCID: PMC11821731 PMID: 39943692 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflicts of interest.
3. Nutrients. 2025 Jan 26;17(3):453. doi: 10.3390/nu17030453. Evaluating Bioactive-Substance-Based Interventions for Adults with MASLD: Results from a Systematic Scoping Review. Handu D(1), Stote K(2), Piemonte T(1). Author information: (1)Academy of Nutrition and Dietetics, Chicago, IL 60606, USA. (2)Department of Allied Health Sciences, State University of New York, Empire State University, Saratoga Springs, NY 12866, USA. Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic condition affecting a broad population. This review aimed to identify and summarize the current evidence on bioactive-substance-based interventions for adults with MASLD, formerly known as nonalcoholic fatty liver disease (NAFLD), covering publications from 2000 to 2023. Methods: A search was conducted across six databases (MEDLINE, CINAHL, Cochrane CENTRAL, Cochrane Database of Systematic Reviews, Food Science Source, and SPORTDiscus) for randomized controlled trials and other study types (e.g., prospective cohort studies and systematic reviews), reflecting the scoping nature of this review. The search was limited to studies in adults (>18 years old), with an intervention of interest and at least one comparator group. Results: A total of 4572 articles were retrieved, with 201 full-text articles screened for eligibility. Of these, 131 primary studies and 49 systematic reviews were included in the scoping review. The most studied bioactive substances were Curcumin (Turmeric) (n = 25), Silymarin (Milk Thistle) (n = 17), Resveratrol (n = 10), Coffee (n = 7), Green Tea (n = 5), and Berberine (n = 5 each). Moreover, 46 studies reported on 36 other bioactive substances with 2 or fewer articles each. Among the included systematic reviews, 13 focused on Curcumin, 12 on Coffee or Tea, 10 on bioactive substance combinations, 6 on Resveratrol, and 2 each on Silymarin and Artichoke Leaf. The included studies showed substantial heterogeneity in reported outcomes, which primarily focused on hepatic health, body weight, adverse events, glycemic control, blood lipids, and body composition. Conclusions: This scoping review highlights a range of bioactive substances used in the treatment of MASLD. While evidence is abundant for bioactive substances like Curcumin and Silymarin, further research and synthesis of findings is necessary to establish the clinical efficacy of all bioactive substances. DOI: 10.3390/nu17030453 PMCID: PMC11820841 PMID: 39940310 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflicts of interest related to this work. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results [197,198,199,200,201,202,203].
4. Am J Cardiovasc Drugs. 2024 Nov;24(6):719-728. doi: 10.1007/s40256-024-00681-1. Epub 2024 Sep 19. A Clinicians Guide to Recommending Common Cholesterol-Lowering Dietary Supplements. Backes JM(1), Hilleman DE(2). Author information: (1)University of Kansas Medical Center, KU School of Pharmacy, 2010 Becker Drive, Lawrence, KS, 66047, USA. jbackes@kumc.edu. (2)Creighton University School of Pharmacy and Health Professions, 2500 California Plaza, Omaha, NE, 68178, USA. The US dietary supplement (DS) market has expanded exponentially since 1994, with an estimated 50,000-80,000 individual products currently available. Many DS claim cholesterol or cardiovascular benefits. Overall, well-designed randomized controlled trials (RCTs) with DS are lacking, while studies with favorable results are commonly performed outside of the USA, resulting in inconsistent findings. The expansion of the DS market has limited the ability of the Food and Drug Administration to regulate and prevent substandard products. Eicosapentaenoic acid and docosahexaenoic acid are components of DS fish oil. Recent RCTs utilizing prescription fish oil have provided mixed findings and small but significant safety concerns. Hence, the role of DS fish oil is limited and no longer recommended by major cardiovascular guidelines. Concerns have also been observed from RCTs utilizing prescription niacin, resulting in a negligible role for DS niacin in lipid management. Red yeast rice has demonstrated significant low-density lipoprotein cholesterol (LDL-C) reductions in studies performed worldwide, including the USA. However, quality concerns and inconsistent study results have been reported on multiple occasions. Other common DS have produced modest reductions in LDL-C and may provide other cardiometabolic benefits, including garlic, phytosterols, psyllium, and berberine. Yet inconsistent study results and quality concerns continue to be reported for most. Nonetheless, there is a need for alternative therapies that can safely and effectively reduce cardiovascular risk. However, until DS routinely match label claims and are free of contaminants, the agents have a limited role in clinical practice. © 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG. DOI: 10.1007/s40256-024-00681-1 PMID: 39297910 [Indexed for MEDLINE]
5. Physiol Rep. 2024 Aug;12(15):e16146. doi: 10.14814/phy2.16146. Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes. Nikseresht M(1), Dabidi Roshan V(1)(2), Nasiri K(1). Author information: (1)Department of Exercise Physiology, Faculty of Sport Science, University of Mazandaran, Babolsar, Iran. (2)Athletic Performance and Health Research Centre, Faculty of Sport Science, University of Mazandaran, Babolsar, Iran. This study compared the capacity of two different models of HIIT [high-(HC) and low-(LC) compression], with or without the use of berberine (BBR), on NOD-like receptor pyrin domain-containing protein-3 (NLRP3), H19, interleukin (IL)-1β, high-sensitivity C-reactive protein (hs-CRP), and insulin resistance markers. Fifty-four middle-aged men with overweight or obesity and prediabetes [fasting blood glucose (FBG) 110-180 mg/dL] were randomly and equally assigned to the HC, LC, HC + BBR, LC + BBR, BBR, and non-exercising control (CON) groups. The HC (2:1 work-to-rest) and LC (1:1 work-to-rest) home-based training programs included 2-4 sets of 8 exercises at 80%-95% HRmax, twice a week for 8 weeks. Participants in the berberine groups received approximately 1000 mg daily. All exercise interventions led to a significant reduction in hs-CRP, IL-1β, insulin, FBG, and insulin resistance index (HOMA-IR) versus CON. Notably, there was a significant reduction in FBG and HOMA-IR with the BBR group compared to the baseline. Both NLRP3 and H19 experienced a significant drop only with LC in comparison to the baseline. While both exercise protocols were beneficial overall, LC uniquely exhibited more anti-inflammatory effects, as indicated by reductions in H19 and NLRP3. However, the addition of berberine to the exercise programs did not demonstrate additional benefits. © 2024 The Author(s). Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society. DOI: 10.14814/phy2.16146 PMCID: PMC11303016 PMID: 39107107 [Indexed for MEDLINE] Conflict of interest statement: The authors declare that no conflict of interest would prejudice their impartiality.
6. Int J Food Sci Nutr. 2024 Jun;75(4):349-368. doi: 10.1080/09637486.2024.2342301. Epub 2024 Apr 24. Dietary supplements: clinical cholesterol-lowering efficacy and potential mechanisms of action. Ge Q(1), Yan Y(1), Luo Y(2), Teng T(3), Cao C(4), Zhao D(1), Zhang J(1), Li C(1), Chen W(1), Yang B(1), Yi Z(5), Chang T(5), Chen X(1). Author information: (1)Institute of Quality Standard and Testing Technology of Agricultural Products, Ningxia Academy of Agriculture and Forestry Sciences, Yinchuan, China. (2)Ningxia Institute of Science and Technology Development Strategy and Information, Yinchuan, China. (3)Ningxia Guolong Hospital Co., LTD, Yinchuan, China. (4)People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, China. (5)College of Food Science and Technology, Huazhong Agricultural University, Wuhan, China. This review aims to analyse the efficacy of dietary supplements in reducing plasma cholesterol levels. Focusing on evidence from meta-analyses of randomised controlled clinical trials, with an emphasis on potential mechanisms of action as supported by human, animal, and cell studies. Certain dietary supplements including phytosterols, berberine, viscous soluble dietary fibres, garlic supplements, soy protein, specific probiotic strains, and certain polyphenol extracts could significantly reduce plasma total and low-density lipoprotein (LDL) cholesterol levels by 3-25% in hypercholesterolemic patients depending on the type of supplement. They tended to be more effective in reducing plasma LDL cholesterol level in hypercholesterolemic individuals than in normocholesterolemic individuals. These supplements worked by various mechanisms, such as enhancing the excretion of bile acids, inhibiting the absorption of cholesterol in the intestines, increasing the expression of hepatic LDL receptors, suppressing the activity of enzymes involved in cholesterol synthesis, and activating the adenosine monophosphate-activated protein kinase signalling pathway. DOI: 10.1080/09637486.2024.2342301 PMID: 38659110 [Indexed for MEDLINE]
7. Front Pharmacol. 2023 Nov 21;14:1269605. doi: 10.3389/fphar.2023.1269605. eCollection 2023. Effect of Berberine Phytosome on reproductive, dermatologic, and metabolic characteristics in women with polycystic ovary syndrome: a controlled, randomized, multi-centric, open-label clinical trial. Di Pierro F(#)(1)(2), Sultana R(#)(3), Eusaph AZ(#)(4), Abrar S(#)(5), Bugti M(6), Afridi F(7), Farooq U(8), Iqtadar S(9), Ghauri F(5), Makhduma S(5), Nourin S(5), Kanwal A(5), Bano A(10), Bugti AA(11), Mureed S(12), Ghazal A(13), Irshad R(14), Recchia M(15), Bertuccioli A(16), Putignano P(17), Riva A(18), Guasti L(2), Zerbinati N(2), Khan A(19)(20). Author information: (1)Scientific and Research Department, Velleja Research, Milan, Italy. (2)Department of Medicine and Surgery, University of Insubria, Varese, Italy. (3)Department of Gynaecology and Obstetrics, Ayub Teaching Hospital, Abbottabad, Pakistan. (4)Department of Gynaecology and Obstetrics, Sir Ganga Ram Hospital, Fatima Jinnah Women University, Rawalpindi, Pakistan. (5)Department of Gynaecology and Obstetrics, Lady Reading Hospital, Peshawar, Pakistan. (6)Department of Gynaecology and Obstetrics, Bolan Medical Complex Hospital, Quetta, Pakistan. (7)Department of Gynaecology and Obstetrics, Khyber Teaching Hospital, Peshawar, Pakistan. (8)Department of Community Medicine, Ayub Teaching Hospital, Abbottabad, Pakistan. (9)Department of Medicine, King Edward Medical University, Lahore, Pakistan. (10)PEOC, Department of Health, Quetta, Balochistan, Pakistan. (11)Department of General Surgery, Bolan Medical Complex Hospital, Quetta, Pakistan. (12)Department of Paediatrics, Bolan Medical Complex Hospital, Quetta, Pakistan. (13)Department of Microbiology, University of Health Sciences, Lahore, Pakistan. (14)14 Department of Pathology, Ayub Teaching Hospital, Abbottabad, Pakistan. (15)Unit of Clinical Epidemiology and Biostatistics, Mario Negri Institute Alumni Association (MNIAA), Milan, Italy. (16)Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy. (17)SP Diabetic Outpatient Clinic, Monza, Italy. (18)Indena S.p.A, Milan, Italy. (19)Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom. (20)Department of Biochemistry, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan. (#)Contributed equally Background: Berberine is a poorly absorbed natural alkaloid widely used as nutraceutical to counteract diarrhoea and to lower cholesterol and hyperglycaemia. It has also been reported to reduce signs and symptoms of polycystic ovary syndrome (PCOS). Objective: To explore, through a multi-centric, randomized, controlled and prospective study, the possible role played by a form berberine that is more easily absorbed (Berberine Phytosome®, BP) in 130 Pakistani women with a diagnosis of PCOS and fertility problems due to menstrual and ovary abnormalities. Results: Ninety days of supplementation with BP, administered at 550 mg x2/die, determined (i) resumption of regular menstruation in about 70% of women (versus 16% in the control group; p < 0.0001), (ii) normalization of the ovaries anatomy in more than 60% of women (versus 13% in the control group; p < 0.0001), (iii) acne improvement in 50% of women (versus 16% in the control group; p = 0.0409) and (iv) hirsutism reduction in 14% of women (versus 0% in the control group; p = 0.0152). The metabolic and the hormonal profiles of the women in the two groups did not significantly differentiate at the end of the study. BP was well-tolerated and no specific side-effects were registered. Respectively after one, two and 8 years of trying, three women supplemented with BP became and are currently pregnant. Conclusion: Our study showed the positive effects of BP supplementation in women with PCOS and confirmed the high safety profile of this nutraceutical. Clinical Trial Registration: https://clinicaltrials.gov/, identifier NCT05480670. Copyright © 2023 Di Pierro, Sultana, Eusaph, Abrar, Bugti, Afridi, Farooq, Iqtadar, Ghauri, Makhduma, Nourin, Kanwal, Bano, Bugti, Mureed, Ghazal, Irshad, Recchia, Bertuccioli, Putignano, Riva, Guasti, Zerbinati and Khan. DOI: 10.3389/fphar.2023.1269605 PMCID: PMC10703476 PMID: 38074133 Conflict of interest statement: FDP belongs to the Scientific Board of Pharmextracta. ABe and PP are Pharmextracta scientific advisers. AR is an Indena’s employee. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
8. Clin Ther. 2024 Feb;46(2):e64-e72. doi: 10.1016/j.clinthera.2023.10.019. Epub 2023 Nov 27. The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-analysis of Randomized Controlled Trials. Nazari A(1), Ghotbabadi ZR(2), Kazemi KS(3), Metghalchi Y(4), Tavakoli R(5), Rahimabadi RZ(6), Ghaheri M(7). Author information: (1)Tehran University of Medical Sciences, Tehran, Iran. (2)Shiraz University of Medical Sciences, Shiraz, Iran. (3)Faculty of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran. (4)Department of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. (5)Department of Radiology, Arak University of Medical Sciences, Arak, Iran. (6)Olomtahghighat University, Tehran, Iran. (7)Student Research Committee, Alborz University of Medical Sciences, Karaj, Iran. Electronic address: Ghaherimohammad98@gmail.com. PURPOSE: Several meta-analyses reported berberine (BBR) supplementation improves glycemic parameters and inflammatory marker, but findings remain inconsistent. Therefore, this study was conducted. METHODS: We systematically searched PubMed, Embase, Web of Science, Scopus, and Google Scholar to identify the relevant meta-analyses up to April 2023. FINDINGS: BBR supplementation was effective in reducing fasting blood glucose (FBG) (ESWMD: -0.77; 95% CI: -0.90 to -0.63, and ESSMD: -0.65; 95% CI: -0.83 to -0.47), hemoglobin A1C (HbA1C) (ESWMD: -0.57; 95% CI: -0.68 to -0.46), homeostasis model assessment for insulin resistance (HOMA-IR) (ESWMD: -1.04; 95% CI: -1.66 to -0.42, and ESSMD: -0.71; 95% CI: -0.97 to -0.46), insulin (ESWMD: -1.00; 95% CI: -1.70 to -0.30, and ESSMD: -0.63; 95% CI: -0.94 to -0.32), interleukin (IL)-6 (ESSMD: -1.23; 95% CI: -1.61 to -0.85), tumor necrosis factor-α (TNF-α) (ESSMD: -1.04; 95% CI: -1.28 to -0.79), and C-reactive protein (CRP) (ESWMD: -0.62; 95% CI: -0.74 to -0.50, and ESSMD: -1.70; 95% CI: -2.21 to -1.19). IMPLICATIONS: The finding of our umbrella showed that the supplementation of BBR could be effective in improving glycemic parameters and inflammatory marker in adults. Copyright © 2023 Elsevier Inc. All rights reserved. DOI: 10.1016/j.clinthera.2023.10.019 PMID: 38016844 [Indexed for MEDLINE] Conflict of interest statement: Declaration of Competing Interest There were no personal or financial conflicts of interest stated by the authors.
9. Arch Med Sci. 2023 Jun 17;19(5):1169-1179. doi: 10.5114/aoms/167969. eCollection 2023. Three arms, double-blind, non-inferiority, randomized clinical study testing the lipid-lowering effect of a novel dietary supplement containing red yeast rice and artichoke extracts compared to Armolipid Plus(®) and placebo. Cicero AFG(1)(2), Fogacci F(1)(2), Tocci G(3), D'Addato S(2), Grandi E(2), Banach M(4)(5)(6)(7), Borghi C(1)(2)(3)(4). Author information: (1)Hypertension and Cardiovascular Risk Research Group, Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy. (2)Italian Nutraceutical Society (SINut), Bologna, Italy. (3)Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy. (4)Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland. (5)Department of Cardiology and Congenital Diseases of Adults, Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland. (6)Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland. (7)Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, United States. INTRODUCTION: There is growing interest in head-to-head comparison between different lipid-lowering nutraceuticals. The aim of our study was to test the lipid-lowering effect of dietary supplementation with low-dose monacolins from red yeast rice (2.8 mg per daily dose) combined with berberine (Armolipid Plus®) or highly standardized artichoke extract versus placebo. MATERIAL AND METHODS: 60 overall healthy adult volunteers with polygenic hypercholesterolemia (baseline low-density lipoprotein cholesterol (LDL-C) = 160.2 ±9.2 mg/dl) were enrolled in a 3-arm, double-blind, non-inferiority, randomized, parallel-group clinical trial. After 4-week diet standardization, enrolled individuals were randomized to be treated for 8 weeks with red yeast rice and highly standardized artichoke extracts (ATC group), Armolipid Plus®, or placebo. RESULTS: At the enrolment visit, LDL-C values were similar in the compared groups. After 8 weeks, all actively treated subjects experienced significant improvements in baseline total cholesterol (TC), LDL-C and apolipoprotein B (Apo-B) (all p < 0.01) (ATC group: TC = -18.9%, LDL-C = -26.7% (placebo-corrected: -12.4%), Apo-B = -19.6%; Armolipid Plus®: TC = -18.4%, LDL-C = -25.8% (placebo-corrected: -12.1%), Apo-B = -23.2%; placebo: TC = -6.2%, LDL-C = -8%, Apo-B = -8.4%). Participants in the ATC group attained significantly lower body mass index (BMI) values (-2.1%), while individuals treated with Armolipid Plus® showed improvements in baseline high-density lipoprotein cholesterol (HDL-C) (+8.7%) and triglyceride (TG) (+17.5%) levels. Finally, baseline hepatic steatosis index (HSI) values significantly decreased in both actively treated groups (by -2.4% and -2.4% in ATC and in Armolipid Plus®, respectively). CONCLUSIONS: Patients with polygenic hypercholesterolemia experienced a significant improvement in several cardiovascular risk factors in both ATC and Armolipid Plus® groups. Copyright: © 2023 Termedia & Banach. DOI: 10.5114/aoms/167969 PMCID: PMC10507752 PMID: 37732047 Conflict of interest statement: The authors declare no conflict of interest.
10. Phytother Res. 2023 Dec;37(12):5541-5557. doi: 10.1002/ptr.7998. Epub 2023 Sep 7. Effects of berberine and barberry on selected inflammatory biomarkers in adults: A systematic review and dose-response meta-analysis of randomized clinical trials. Vahedi-Mazdabadi Y(1)(2), Shahinfar H(1)(2), Toushih M(3)(4), Shidfar F(2)(5). Author information: (1)Student Research Committee, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. (2)Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. (3)Department of Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. (4)Cardiac Primary Prevention Research Center, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. (5)Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran. The previous meta-analysis showed an advantageous effect of berberine supplementation on interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α), and serum C-reactive protein (CRP) concentrations; however, it is unknown the dosage that this component influences inflammatory biomarkers. A comprehensive search was done in Scopus, PubMed, and Web of Science until September 2022 to find randomized controlled trials (RCT) that assessed the effects of berberine/barberry on IL-6, TNF-α, and CRP in adults but not trials without a control group. Studies bias was assessed using RoB 2. A random-effects model was performed to calculate the weighted mean difference (WMD). A dose-dependent effect was calculated. Eighteen clinical trials with 1600 participants were included in the current meta-analysis. These interventions significantly mitigate IL-6 levels (-1.18 pg/mL), TNF-α levels (-3.72 pg/mL), and CRP levels (-1.33 mg/L). In addition, the non-linear analysis showed a significant lowering effect of berberine/barberry on IL-6 and TNF-α levels in doses <1000 mg/day and less than 5 weeks of intervention. There are limitations to our findings, including low-quality studies and significant heterogeneity. These interventions might be considered adjunct therapy to managing inflammation status. However, more investigation and high-quality evidence must be conducted to obtain more comprehensive and generalizable results. © 2023 John Wiley & Sons Ltd. DOI: 10.1002/ptr.7998 PMID: 37675930 [Indexed for MEDLINE]
11. J Nutr. 2023 Oct;153(10):2939-2950. doi: 10.1016/j.tjnut.2023.08.016. Epub 2023 Aug 19. Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials. Zhao JV(1), Huang X(2), Zhang J(2), Chan YH(3), Tse HF(3), Blais JE(2). Author information: (1)School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. Electronic address: janezhao@hku.hk. (2)School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. (3)School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. BACKGROUND: Berberine is widely available as a nutraceutical supplement for improving glucose metabolism. Berberine affects sex hormones, raising the possibility that its effects on glycemic traits and insulin sensitivity have sex disparity which has been overlooked. OBJECTIVE: To assess the overall and sex-specific effects of berberine on glycemic- and insulin-related traits. METHODS: We identified randomized trials of berberine versus placebo from Medline, Embase, CNKI, clinical trial registries and previous systematic reviews. Mean differences were estimated using inverse-variance weighting with random effects models. Subgroup analyses were conducted by sex, diabetes diagnosis, trial duration, berberine dose and ethnicity. RESULTS: We identified 20 eligible studies (n = 1761). Berberine lowered fasting glucose (-0.52 mmol/L, 95% CI -0.72 to -0.33; 18 studies, n = 1522), HbA1c (-4.48 mmol/mol, 95% CI -6.53 to -2.44, 7 studies, n = 756), fasting insulin (-2.36 mU/L, 95% CI -3.64 to -1.08, 11 studies, n = 966), HOMA-IR (-0.85, 95% CI -1.16 to -0.53,12 studies, n = 1065), and 2-h postprandial glucose (-1.81 mmol/L, 95% CI -2.37 to -1.24, 4 studies, n = 501). Effects on fasting glucose and HOMA-IR showed potential differences by sex, with larger reductions in women than in men. Comparing 4 studies conducted in women to one study conducted in men, the mean difference was -0.21 mmol/L (95% CI -0.41 to -0.00) for fasting glucose and -0.97 (95% CI -1.84 to -0.10) for HOMA-IR. We also found larger reductions in fasting glucose in participants with diabetes and in Asians. CONCLUSION: Berberine is effective in improving glucose metabolism and may result in larger effects on fasting glucose in women, in people with diabetes and in Asians, but subgroup comparisons remain to be replicated given the limited number of studies. Berberine can be considered as a complementary intervention in individuals who may benefit from modest improvements in glucose metabolism and who prefer taking a nutraceutical. STUDY REGISTRATION: PROSPERO (CRD42022345172). Copyright © 2023 American Society for Nutrition. Published by Elsevier Inc. All rights reserved. DOI: 10.1016/j.tjnut.2023.08.016 PMID: 37598753 [Indexed for MEDLINE]
12. Eur Rev Med Pharmacol Sci. 2023 Jul;27(14):6718-6727. doi: 10.26355/eurrev_202307_33142. Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial. Rondanelli M(1), Gasparri C, Petrangolini G, Allegrini P, Avenoso D, Fazia T, Bernardinelli L, Peroni G, Patelli Z, Mansueto F, Tartara A, Cavioni A, Riva A. Author information: (1)Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy. clara.gasparri01@universitadipavia.it. OBJECTIVE: Berberine is a plant alkaloid known to exert positive metabolic effects. Human studies have confirmed its ability to improve the lipid and glycemic profile. This study aimed to evaluate the potential benefit of oral supplementation of Berberine PhytosomeTM (2 tablets/day, 550 mg/tablet) on the metabolic profile of subjects with impaired fasting blood glucose (IFG). PATIENTS AND METHODS: A total of 49 overweight subjects, 28 females and 21 males, were randomly assigned to either the supplemented group (n=24) or placebo (n=25). We considered glycemia as the primary endpoint and total cholesterol, high-density lipoprotein (HDL), total cholesterol/HLD, low-density lipoprotein (LDL), LDL/HDL, triglycerides, insulin, glycated hemoglobin, Homeostasis Model Assessment (HOMA), ApoA, ApoB, ApoB/ApoA, androgen suppression treatment (AST), alternative lengthening of telomeres (ALT), gamma-glutamyl transferase (GGT), creatinine, and body composition by dual-energy X-ray absorptiometry (DXA) as secondary endpoints. These parameters have been assessed at baseline, after 30 days, and after 60 days. RESULTS: After two months of treatment, through the use of linear mixed effect models, a statistically significant difference between supplemented and placebo groups was observed for glycemia [β=-0.2495% C.I. (-0.47; -0.06), p=0.004], total cholesterol [β=-0.25, 95% C.I. (-0.45; -0.04), p=0.05], total cholesterol/HDL [β=-0.25, 95% C.I. (-0.43; -0.06), p=0.04], triglycerides [β=-0.14, 95% C.I. (-0.25; -0.02), p=0.05], insulin [β=-1.78, 95% C.I. (-2.87; -0.66), p=0.009], ApoB/ApoA [β=-0.08, 95% C.I. (-0.13; -03), p=0.004], Visceral adipose tissue (VAT) [β=-91.50, 95% C.I. (-132.60; -48.19), p<0.0001] and fat mass [β=-945.56, 95% C.I. (-1,424.42; -441.57), p=0.004]. CONCLUSIONS: The use of berberine had no adverse events, supporting its use as a natural alternative to pharmacological therapies in the case of IFG. DOI: 10.26355/eurrev_202307_33142 PMID: 37522683 [Indexed for MEDLINE]
13. Integr Med (Encinitas). 2023 Mar;22(1):30-38. A Comprehensive Review of Herbal Supplements Used for Persistent Symptoms Attributed to Lyme Disease. Thompson A(1), Hynicka LM(2), Shere-Wolfe KD(3). Author information: (1)Doctor of Pharmacy candidate. (2)Associate professor of Pharmacotherapy Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD, USA. (3)Assistant Professor of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. CONTEXT: Lyme disease is the most common, tick-borne disease in the USA. While most patients successfully recover with antibiotics, some patients experience persistent symptoms for months to years. Patients who attribute chronic symptoms to Lyme disease commonly use herbal supplements. The complexity, variability in dose and formulation, and lack of data for these herbal compounds make it difficult to assess their efficacy and safety. OBJECTIVE: This review examines the evidence for the antimicrobial activity, safety, and drug-drug interactions of 18 herbal supplements that patients commonly use for treatment of persistent symptoms attributed to Lyme disease. DESIGN: The research team performed a narrative review by searching the PubMed, Embase, Scopus, Natural Medicines databases, and NCCIH website. The search used the keywords for 18 herbal compounds: (1) andrographis (Andrographis paniculate), (2) astragalus (Astragalus propinquus), (3) berberine, (4) cat's claw bark (Uncaria tomentosa), (5) cordyceps (Cordyceps sinensis), (6) cryptolepis (Cryptolepis sanguinolenta), (7) Chinese skullcap (Scutellaria baicalensis), (8) garlic (Allium sativum), (9) Japanese knotwood (Polygonum cuspidatum), (10) reishi mushrooms (Ganoderma lucidum), (11) sarsaparilla (Smilax medica), (12) Siberian ginseng (Eleutherococcus senticosus), (13) sweet wormwood (Artemisia annua), (14) teasle root (Dipsacus fullonum), (15) lemon balm (Melissa officinalis), (16) oil of oregano (Origanum vulgare), (17) peppermint (Mentha x piperita), and (18) thyme (Thymus vulgaris). The team also searched for terms related to protocols, including Dr. Rawls' protocol and the Buhner protocol. SETTING: University of Maryland Medical Center, Baltimore MD. RESULTS: Seven of the 18 herbs reviewed had evidence for in-vitro activity against B. burgdorferi. These compounds included: (1) cat's claw (2) cryptolepis, (3) Chinese skullcap, (4) Japanese knotweed, (5) sweet wormwood, (6) thyme, and (7) oil of oregano. With the exception of oil of oregano these compounds also have anti-inflammatory activity. In vivo data and clinical trials are lacking. Clinicians should be cautious as many of the identified compounds have drug interactions and additive effects that could lead to increased risks for bleeding, hypotension, and hypoglycemia. CONCLUSIONS: Many of the herbs that alternative and integrative practitioners use to treat Lyme disease have anti-inflammatory effects that may contribute to patients' perceptions of symptomatic improvement. Some herbs have limited demonstrated anti-borrelial activity in vitro, but in-vivo data and clinical trial data is lacking. Further research is required to determine the efficacy, safety and appropriate use of these herbs for this patient population. Copyright © 2023 InnoVision Professional Media Inc. PMCID: PMC10124234 PMID: 37101730
14. Drugs. 2023 Apr;83(5):403-427. doi: 10.1007/s40265-023-01841-4. Epub 2023 Mar 21. Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Blais JE(1)(2), Huang X(1), Zhao JV(3). Author information: (1)School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. (2)Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. (3)School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. janezhao@hku.hk. BACKGROUND: Berberine is a nutraceutical that can improve lipid metabolism. Berberine may also affect sex hormones and exert sex-specific lipid-modifying effects, which have been overlooked. This study aimed to comprehensively review the efficacy and safety of berberine in adults for the treatment of dyslipidemia with consideration of potential sex disparity. Data Sources We searched Medline, Embase, Wanfang, CNKI, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform from inception to 13 December 2022. No language restrictions were applied. This study was registered in PROSPERO (CRD42021293218) prior to completing the literature search. Study Selection Two blinded reviewers assessed studies for inclusion. Eligible studies were randomized controlled trials in adults that compared berberine versus placebo, and measured blood lipids or lipoproteins. Data Extraction and Synthesis Data extraction was performed by two blinded reviewers using a structured form in Covidence. Risk of bias was assessed using the Cochrane risk of bias tool for randomized trials. Mean differences (MD) were estimated using inverse variance weighting with random effects models for lipid outcomes using R. Adverse events (AEs) were described narratively. Main Outcomes Primary outcomes were low-density lipoprotein (LDL) cholesterol, total cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, and apolipoprotein B. Secondary outcomes were gastrointestinal and muscle-related AEs. RESULTS: Eighteen studies (n = 1788 participants), conducted mainly in mainland China and Hong Kong (15 studies [83%]), were included with treatment durations ranging from 4 to 24 weeks. Berberine reduced LDL cholesterol (- 0.46 mmol/L, 95% CI - 0.62 to - 0.30, 14 studies, n = 1447), total cholesterol (- 0.48 mmol/L, 95% CI - 0.63 to - 0.33, 17 studies, n = 1637), triglycerides (- 0.34 mmol/L, 95% CI - 0.46 to - 0.23, 18 studies, n = 1661) and apolipoprotein B (- 0.25 g/L, 95% CI - 0.40 to - 0.11, 2 studies, n = 127). Berberine increased HDL cholesterol by 0.06 mmol/L (95% CI 0.00 to 0.11, 15 studies, n = 1471). Notably, the effect on HDL cholesterol was different in women (0.11 mmol/L, 95% CI 0.09 to 0.13) from that in men (- 0.07 mmol/L, 95% CI - 0.16 to 0.02). Among 16 studies that reported AEs, no serious AEs were reported for berberine. Gastrointestinal AEs were reported in 12 studies and tended to be more frequent in participants allocated to berberine versus placebo (2-23% vs 2-15%). CONCLUSIONS: Berberine produces small reductions in LDL cholesterol, triglycerides, and apolipoprotein B, with potential sex-specific effects on HDL cholesterol. Large-scale trials that consider sex disparity and assess clinical outcomes are required. Plain Language Summary: Berberine is found naturally in barberry and goldenthread, plants which have long been used in traditional herbal medicine in Asia. Nowadays berberine is used as a purified product and is easy to purchase as a nutraceutical supplement or non-prescription drug. People with dyslipidemia, a medical condition often known as ‘high cholesterol’, may prefer treatment with a nutraceutical such as berberine to reduce blood cholesterol. In recent years, many studies have contrasted the effects of taking berberine with an inactive placebo. This study aimed to combine all the available randomized controlled trials that assessed berberine’s effects on blood lipids and lipoproteins. We included 18 studies that used berberine doses of 900–1500 mg/day, the majority of which were conducted in mainland China and Hong Kong. We found that on average berberine can modestly reduce low-density lipoprotein (LDL) cholesterol by 0.5 mmol/L (18 mg/dL) and triglycerides by 0.3 mmol/L (30 mg/dL). Berberine also increases high-density lipoprotein (HDL) cholesterol by 0.06 mmol/L (2 mg/dL). Interestingly, women may obtain a greater increase in HDL cholesterol than men. The short-term use of berberine appears to be safe. No study participants treated with berberine experienced a serious adverse event. However, berberine may occasionally cause constipation, diarrhea, or nausea. Larger high-quality studies are still needed to determine the long-term effects of berberine for dyslipidemia. © 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG. DOI: 10.1007/s40265-023-01841-4 PMID: 36941490 [Indexed for MEDLINE]
15. Clin Nutr ESPEN. 2022 Jun;49:181-186. doi: 10.1016/j.clnesp.2022.01.037. Epub 2022 Feb 15. Effects berberine-silymarin on liver enzymes: A systematic review and meta-analysis of randomized controlled trials. Mohtashaminia F(1), Amini MR(2), Sheikhhossein F(3), Djafarian K(3), Shab-Bidar S(4). Author information: (1)Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran. (2)Student Research Committee, Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran. (3)Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran. (4)Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran. Electronic address: s_shabbidar@tums.ac.ir. BACKGROUND & AIMS: Despite controversies, no study has systematically summarized findings from earlier studies on the effect of berberine (BBR)-silymarin on liver enzymes. Therefore, the current systematic review and meta-analysis aimed to investigate the effect of berberis aristate and Silybum marianum on alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in adults. METHODS: Relevant studies, published up to June 2021, were searched through PubMed/Medline, Scopus, ISI Web of Science, EMBASE and Google Scholar. The mean differences and standard deviations were pooled using a random-effects model. The studies' quality was evaluated using the Cochrane Risk of Bias Tool. RESULTS: Out of 80 citations, 5 trials that enrolled 549 participants were included. Berberis aristate and Silybum marianum resulted in no statistically significant change in ALT (weighted mean differences (WMD): -0.39 mg/dl; 95% CI: -1.67 to 0.89, P = 0.55), and AST (WMD: -0.44 mg/dl; 95% CI: -2.02 to 1.14, P = 0.58). CONCLUSION: We did not find any significant reduction in liver enzymes following BBR-silymarin consumption in adults. Further clinical trials with high quality according to the challenges mentioned seem to be helpful to use BBR-silymarin as a supplement for improving liver function. Copyright © 2022 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved. DOI: 10.1016/j.clnesp.2022.01.037 PMID: 35623810 [Indexed for MEDLINE] Conflict of interest statement: Declaration of competing interest The authors declared no conflicts of interest.
⚠️ 면책 고지
이 정보는 일반 교육 목적이며 의료 진단/처방을 대체하지 않습니다.